HR+/HER2- advanced breast cancer, CDK4/6 inhibitors, Real-world, progression-free survival, Lobular histology, PALMARES-2
Ovarian function suppression, HER2 positive, adjuvant endocrine therapy, aromatase inhibitors, tamoxifen, LHRH agonists, neoadjuvant, residual disease, pathological complete response
Breast Cancer, oligoprogression, Progression-directed radiation therapy, Event-free survival
breast cancer, Oligoprogression, Progression-directed radiation therapy, Event-free survival
Breast Cancer, HER2-low, machine-learning
breast cancer, HER2-low, machine-learning